ArticleFrontiers in bioengineering and biotechnology2026
A hydrogel platform delivering mesenchymal stem cell lysate for potential myocardial tissue repair.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myocardial infarction is one of the most significant causes of death worldwide and the limited regenerative capacity of the myocardium often results in poor recovery after injury. Stem cell therapy has some promise for myocardial tissue repair, but clinical translation is hindered by poor cell survival and safety concerns, prompting the investigations of cell-free strategies such as stem cell-derived secretome or lysate. Methods: In this study, a quaternized chitosan/tannic acid hydrogel was fabricated and characterized for its crosslinking stability, injectability and degradation kinetics. In addition, mouse adipose-derived mesenchymal stem cells (mADSCs) were isolated, characterized, and processed into cell-free lysate. The mADSCs lysate was then analyzed by TEM, NTA, Western blot and enzyme-linked immunosorbent assay. Results: It was found that the mADSCs lysate contained abundant vesicles and a broad panel of cytokines/growth factors with anti-inflammatory, pro-angiogenic and antioxidant properties. Encapsulating the lysate within the hydrogel showed sustained release. The hydrogel-based delivery of mADSCs lysate could promote high metabolic activity and good cell number increases of H9c2-cardiomyocytes, L929-fibroblasts and human umbilical vein endothelial cells, demonstrating great potential for myocardial tissue repair applications. Discussion: By integrating the regenerative potential of ADSCs lysate with this biocompatible, injectable hydrogel platform, this combined strategy circumvents the potential safety issues associated with live cell transplantation and offers a scalable, potential cell-free delivery strategy for myocardial repair-related applications, laying a foundation for future
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.